| Expression pattern: |
UP |
| Associated gene: |
Cyclin A1, PCNA, Bax, Cleaved caspase-3 |
| Associated microRNA: |
miR-139-3p |
| Biological function: |
promotes GC cell proliferation and tumor growth; inhibits cell apoptosis |
| Molecular mechanism: |
circPTK2 acts as a sponge of miR-139-3p; circPTK2 knockdown decreases Cyclin A1 and PCNA and increases Bax and Cleaved caspase-3; miR-139-3p inhibition reverses circPTK2 knockdown-mediated effects on proliferation, apoptosis, and tumor growth |
| Biological pathway or process: |
proliferation (promotes); apoptosis (inhibits); ceRNA regulation (promotes); other pathway/process (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; Bioinformatics Analysis; Transfection; Colony Formation Assay; Annexin V/PI Flow Cytometry; Western Blot; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); In Vivo Animal Model |
| Clinical significance: |
circPTK2 expression was associated with TNM stage, lymph node metastasis, and tumor size; it may function as an effective gene target for managing GC |
| Description: |
circPTK2 is up-regulated in gastric carcinoma tissues and cell lines. It promotes GC cell proliferation and xenograft tumor growth while inhibiting apoptosis, at least partly by sponging miR-139-3p and regulating proliferation- and apoptosis-related factors including Cyclin A1, PCNA, Bax, and Cleaved caspase-3. Its expression is associated with TNM stage, lymph node metastasis, and tumor size, suggesting potential clinical relevance as a therapeutic target. |
| Confidence score: |
0.7032 |